Login to Your Account

Care MS II Disability Data Fuel Lemtrada's Ongoing Progress

By Cormac Sheridan
Staff Writer

Wednesday, April 25, 2012
Genzyme unveiled new disability data from the Care MS II Phase III head-to-head trial of its CD52-targeting antibody, Lemtrada (alemtuzumab), which confirmed its superiority over Rebif (interferon beta-1a) in patients with relapsing-remitting multiple sclerosis (MS) who had relapsed on prior therapy.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription